Background: Immunotherapy with immune-checkpoint molecule inhibitors such as anti-CTLA4, anti-PD-1 and anti-PD-L1 increases the overall survival of melanoma patients with or without BRAF V600 mutations. Here, PDCD1 is linked to melanoma.